Destigmatizing Urology: Dr. Winter discusses STDs/STIs

"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.

In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.

The study is assessing RECCE 327 across the infusion times of 15, 20, 30, 45, and 60 minutes at the dose level of 3000 mg.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

"We have over 30 years of safety data, and no adverse events in over 30 years," says Heather Florio.

Liposomal tacrolimus led to improvements in hematuria, bleeding sites on cystoscopy, microscopic urine analysis for red blood cells, and urinary symptoms.